Turn research into medicines

WEBINAR

for Shareholders and Individual Investors

To mark the release of its 2025 annual results, Aton Group (Euronext Growth Paris – FR0004153930 – ALTAO), a company specializing in the medical sciences sector, is pleased to invite its shareholders and all individual investors to a videoconference:

Tuesday, May 12, 2026, at 6:00 p.m.

During this videoconference, Léone Atayi, Chief Executive Officer, and Hadrien Lanvin, Deputy Chief Executive Officer, will discuss the company’s 2025 results and its outlook. They will also provide an update on the progress made by the Company and its subsidiaries (B Cell Design, PIMS Technology, and Inoviem Scientific) within the therapeutic treatment value chain serving players in the pharmaceutical and biotechnology industries.

They will also answer questions from shareholders and individual investors.

Aton shareholders and individual investors may already submit their questions via email to aton@actus.fr.

Register here

OUR PURPOSE

Our driving purpose is to advance therapies for the good of patients, medicine and society.

Our cutting-edge companies work in synergy, to accelerate and advance testing and development of effective medicines. Our aim is to give every patient access to tomorrow’s therapies: the right treatment, to the right person, at the right time.

Learn more

OUR PLATFORMS

Game-changing life science platforms

Our platforms are driving a fundamental shift to provide opportunities for more personalization and precision products and services. Diverse platforms, each with unique world-leading technologies and a team of experts united by one desire, to advance and accelerate medical discoveries for the good of patients, medicine, and society. Aton’s platforms bring significant expertise to guide and support life science businesses in achieving their goals with greater efficiency.

Preclinical & Clinical Services

We accelerate and secure the entire drug development process with a patient-centred approach, optimizing our customers' time and resources so...

Learn more

Monoclonal Antibodies Production

Bcell Design is a leading provider of leading-edge monoclonal antibodies with human Fc for companies specializing in in vitro diagnostic...

Learn more

Laboratory Equipment Production

Its accuracy and sensitivity surpass traditional methods, facilitating real-time analysis and personalized medicine. Unravel the complexities of molecular behaviors and...

Learn more

Human Tissue Provision

We ensure that all clinical tissues are procured through rigorous ethical guidelines, with informed consent obtained from donors.

Learn more

INVESTORS

Accelerating the pursuit of tomorrow’s therapies

Turn perspectives into reality. Turn present into future. Turn risk into opportunity. Turn investment into journey. Turn research into medicine. Turn to Aton.

Investor Center